Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Short Interest Update

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) was the target of a significant decline in short interest in September. As of September 30th, there was short interest totalling 27,400 shares, a decline of 24.7% from the September 15th total of 36,400 shares. Approximately 2.1% of the company’s stock are short sold. Based on an average daily volume of 129,700 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 16th.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc acquired 3,000 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were purchased at an average price of $14.89 per share, with a total value of $44,670.00. Following the transaction, the insider now directly owns 127,331 shares in the company, valued at approximately $1,895,958.59. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.89% of the stock is currently owned by corporate insiders.

Pieris Pharmaceuticals Price Performance

NASDAQ:PIRS traded down $0.14 during trading hours on Tuesday, hitting $16.13. 7,615 shares of the company were exchanged, compared to its average volume of 50,015. The company’s 50 day moving average price is $16.89 and its 200-day moving average price is $13.16. The stock has a market capitalization of $21.29 million, a price-to-earnings ratio of -1.36 and a beta of 0.67. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $23.20.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative return on equity of 101.29%.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.